239 related articles for article (PubMed ID: 37403010)
21. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
22. Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.
Martin A; Castells J; Allibert V; Emerit A; Zolotoff C; Cardot-Ruffino V; Gallot YS; Vernus B; Chauvet V; Bartholin L; Schaeffer L; Durieux AC; Hourdé C; Favier FB; Mazelin L; Freyssenet D
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1686-1703. PubMed ID: 35277933
[TBL] [Abstract][Full Text] [Related]
23. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
24. Biological sex divergence in transcriptomic profiles during the onset of hindlimb unloading-induced atrophy.
Tsitkanou S; Morena da Silva F; Cabrera AR; Schrems ER; Murach KA; Washington TA; Rosa-Caldwell ME; Greene NP
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1276-C1293. PubMed ID: 37746697
[TBL] [Abstract][Full Text] [Related]
25. The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.
Bohnert KR; Goli P; Roy A; Sharma AK; Xiong G; Gallot YS; Kumar A
Mol Cell Biol; 2019 Aug; 39(15):. PubMed ID: 31138662
[TBL] [Abstract][Full Text] [Related]
26. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
27. β‑carotene attenuates muscle wasting in cancer cachexia by regulating myogenesis and muscle atrophy.
Kim Y; Oh Y; Kim YS; Shin JH; Lee YS; Kim Y
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37975253
[TBL] [Abstract][Full Text] [Related]
28. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
29. An integrative transcriptome study reveals Ddit4/Redd1 as a key regulator of cancer cachexia in rodent models.
Niu M; Li L; Su Z; Wei L; Pu W; Zhao C; Ding Y; Wazir J; Cao W; Song S; Gao Q; Wang H
Cell Death Dis; 2021 Jun; 12(7):652. PubMed ID: 34175899
[TBL] [Abstract][Full Text] [Related]
30. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
32. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1.
Chen C; Ju R; Zhu L; Li J; Chen W; Zhang DC; Ye CY; Guo L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):423-433. PubMed ID: 28124088
[TBL] [Abstract][Full Text] [Related]
33. LP07 and LLC preclinical models of lung cancer induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting.
Belcher DJ; Guitart M; Hain B; Kim HG; Waning D; Barreiro E; Nader GA
J Appl Physiol (1985); 2022 Dec; 133(6):1260-1272. PubMed ID: 36201324
[TBL] [Abstract][Full Text] [Related]
34. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
35. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models.
Sun R; Zhang S; Lu X; Hu W; Lou N; Zhao Y; Zhou J; Zhang X; Yang H
Oncol Rep; 2016 Dec; 36(6):3291-3302. PubMed ID: 27748895
[TBL] [Abstract][Full Text] [Related]
36. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia.
Bohnert KR; Gallot YS; Sato S; Xiong G; Hindi SM; Kumar A
FASEB J; 2016 Sep; 30(9):3053-68. PubMed ID: 27206451
[TBL] [Abstract][Full Text] [Related]
38. Targeting FFA1 and FFA4 receptors in cancer-induced cachexia.
Freitas RDS; Muradás TC; Dagnino APA; Rost FL; Costa KM; Venturin GT; Greggio S; da Costa JC; Campos MM
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E877-E892. PubMed ID: 32893672
[TBL] [Abstract][Full Text] [Related]
39. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
40. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.
Braun TP; Grossberg AJ; Krasnow SM; Levasseur PR; Szumowski M; Zhu XX; Maxson JE; Knoll JG; Barnes AP; Marks DL
FASEB J; 2013 Sep; 27(9):3572-82. PubMed ID: 23733748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
